The Latest Breaking News from IQV

The company will leverage Nvidia’s prowess in AI to build proprietary models.

IQVIA Holdings has considerably underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.

IQVIA Holdings has underperformed the broader market over the past year, but Wall Street analysts are bullish about the stock’s prospects.

With IQVIA Holdings gearing up to release its third-quarter earnings later this month, analysts project a double-digit surge in earnings.

Despite IQVIA Holdings’ underperformance compared to the S&P 500 Index over the past year, Wall Street analysts remain optimistic about the stock’s prospects.

IQVIA Holdings has underperformed the broader market this year, but Wall Street analysts are bullish about the stock’s prospects.

IQVIA Holdings has underperformed other healthcare stocks over the past three months, but analysts are optimistic about the stock’s prospects.

The increased demand for healthcare services and technological advancements are poised to keep the healthcare industry buoyed in the foreseeable future. Given this backdrop, are medical stocks Danaher Corporation (DHR), IQVIA Holdings (IQV), and Bio-Rad Laboratories (BIO) worth buying now? Read on to find more….

The market turmoil this year, due to the sky-high inflation and the Fed’s hawkish tilt, has led several fundamentally solid large-cap stocks to trade below their intrinsic values. However, we believe quality large-cap stocks Broadcom (AVGO), Abbott (ABT), IQVIA (IQV), Agilent (A), and QUALCOMM (QCOM), which have declined significantly in…

Integration of advanced technologies and analytics in diagnosing chronic diseases at their early stages has helped the medical diagnostics and research industry grow substantially over the past few years. Growing demand and rising investments in R&D should help prominent players in this space, IQVIA Holdings (IQV) and Mettler-Toledo (MTD), benefit.…

IQVIA Holdings Inc (NYSE:IQV) posted Q1 sales of $3.57 billion, up 4.7% on a reported basis and 6.8% at constant currency (CC), slightly above the consensus of $3.55 billion. Technology & Analytics Solutions revenue increased 6.8% (9.8% CC) to $1.44 billion.  Research & Development Solutions (R&DS) sales reached $1.93 billion, +3.5% (4.7%…